Research ArticleHIV

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals

See allHide authors and affiliations

Science Translational Medicine  03 Oct 2018:
Vol. 10, Issue 461, eaau4711
DOI: 10.1126/scitranslmed.aau4711

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • RE: Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals
    • Dianne Sika-Paotonu, Associate Dean (Pacific)/Senior Lecturer Pathology & Molecular Medicine, Wellington School of Medicine & Health Sciences, University of Otago, New Zealand

    To the Editor,

    I read with interest the research article prepared by Uzzan M., et al. (1) and entitled: “Anti-a4B7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.”

    Studies have demonstrated the strong efficacy and safety profile for anti-a4B7 therapy for treating IBD patients. This study explored the role of anti-a4B7 in HIV-infection within a cohort of HIV patients on antiretroviral therapy and receiving anti-a4B7 vedolizumab for concomitant IBD.

    A consequence of anti-a4B7 administration in this context was observed as being the disruption of localized lymphoid aggregates in the gut and peripheral immune populations. The GI tract lymphoid aggregate disruption is of clinical relevance given that these aggregate locations function as viral reservoirs during HIV-1 infection.

    These lymphoid aggregates also contain CD4+T cells that express a4B7 and offer a potential and important target for an anti-a4B7D therapeutic approach for HIV-1. CD4+T cells expressing the a4B7 integrin are reportedly early targets of HIV-1 infection and can be found within the lymphoid aggregates.

    This work demonstrated the safety and tolerability of anti-a4B7 vedolizumab when administered to human patients with HIV-1 infection to treat mild IBD.

    Although a limitation of this study was the low sample size of the study cohort, the potential clinical application of these findings for HIV therapeutics and eradicati...

    Show More
    Competing Interests: None declared.